血漿の世界市場規模：成分別、エンドユーザー別、地域範囲別および予測

血漿の市場規模と予測

血漿市場規模は2024年に412億6,000万米ドルと評価され、2026～2032年にかけてCAGR 9.2%で成長し、2032年には834億4,000万米ドルに達すると予測されます。

• 血漿は、血液細胞（赤血球、白血球、血小板）を除去した後に残る、黄色がかった液体成分です。全血液量の約55％を占める血漿は、主に水（約90％）とタンパク質、電解質、ホルモン、栄養素、老廃物から構成されています。
• 血漿は、これらの物質を全身に運搬する重要な媒体として機能し、血圧、pHバランス、全体的な恒常性の維持に不可欠な役割を果たしています。
• 血漿は、特に輸血医療や治療において、数多くの医療用途があります。血漿は、血友病患者用の凝固因子濃縮製剤の製造に不可欠であり、様々な免疫不全を治療するための免疫グロブリンの製剤にも使用されます。
• さらに、アルブミンや凝固因子などの血漿由来製品は、肝疾患、ショック、火傷などの状態を管理するのに不可欠です。近年、血漿は、創傷治癒や美容治療への応用など、再生医療における可能性でも注目を集めています。

世界の血漿市場力学

世界の血漿市場を形成している主要市場力学は以下の通りです。

主要市場の促進要因

• 血漿由来治療に対する需要の高まり：血漿由来の治療に対する需要の高まりが、血漿市場を大きく牽引しています。血友病や免疫不全などの治療には、効果的な治療のためにこれらの治療が必要です。Plasma Protein Therapeutics Association（PPTA）によると、血漿由来療法の世界市場は2023年に286億米ドルに達し、2028年のCAGRは6.8%と予測されています。
• 献血に対する意識の高まり：献血の重要性に対する意識の高まりにより、血漿の入手可能性が高まっています。公衆衛生キャンペーンは、より多くの人々に献血を奨励し、それによって血漿供給を拡大しています。Plasma Protein Therapeutics Association（PPTA）によると、血漿由来療法の世界市場は2023年に286億米ドルに達し、2028年のCAGRは6.8%と予測されています。
• 慢性疾患の発生率の増加：自己免疫疾患などの慢性疾患の増加により、血漿製品のニーズが高まっています。この動向は、複雑な健康状態の管理における血漿の重要な役割を強調しています。米国疾病予防管理センター（CDC）によると、2023年時点で米国人口の推定6%が自己免疫疾患と共存しており、2018年の4.5%から増加しています。
• バイオテクノロジーへの投資の増加：バイオテクノロジーと研究への投資の増加は、血漿由来製品の開発を強化しています。加工と製剤における革新は、より効果的な治療と用途の拡大につながっています。米国国立衛生ラボ（NIH）の報告によると、血漿由来療法に関連する研究費は2023会計年度に12億米ドルに達し、前年度から15％増加しました。
• 血漿製品に対する規制上の支持の高まり：血漿製剤の安全性と有効性に対する規制当局の支持の高まりは、市場の信頼を醸成しています。このような支援環境は、メーカーが品質改善や新製品開発に投資することを後押ししています。FDAは、2023年に承認される血漿由来治療の数が2020年比で30%増加すると報告しているが、これは承認プロセスがより合理化され、これらの製品に対する信頼が高まっていることを反映しています。

主要課題

• 規制の厳格化：血漿の採取と使用をめぐる規制の厳格化は、市場の拡大を妨げる可能性があります。厳格なガイドラインへの準拠は、製造業者や販売業者にとって複雑さとコストを増大させています。
• ドナーの安全性に対する懸念の高まり：ドナーの安全性と副作用の可能性に関する懸念の高まりは、血漿供給に影響を及ぼす可能性があります。こうした懸念が献血を敬遠させ、血漿の供給不足につながる可能性があります。
• 高まる社会的認知の問題：献血や血漿製品に関連する社会的認知の問題が拡大し、市場成長の障壁となる可能性があります。誤った情報や否定的な感情は、潜在的な献血者や消費者の足を引っ張る可能性があります。
• 代替療法との競合の激化：代替療法や治療法との競合の激化は、血漿市場にとって課題となります。新たな技術が代替療法を提供し、従来型血漿由来療法への依存度を低下させる可能性があります。

主要動向

• 免疫グロブリン療法への注目の高まり：免疫グロブリン療法への注目の高まりが血漿市場に変化をもたらしています。免疫不全や自己免疫疾患に対する免疫グロブリン療法の有効性に対する認識が高まるにつれ、需要が急増しています。ヘルスケアプロバイダによる免疫グロブリン療法の配合が増加し、血漿の収集と処理への投資が拡大しています。この動向は、現代医療における血漿由来製品の重要な役割を浮き彫りにしています。
• 血漿由来の生物製剤に対する需要の高まり：様々な病状の管理に不可欠な凝固因子やアルブミンなどの血漿由来の生物製剤に対する需要が高まっています。この動向に拍車をかけているのが、慢性疾患、外科手術、外傷治療のニーズの増加です。これらの救命療法を必要とする患者が増えるにつれ、メーカーはこの需要に応えるべく製品ラインを拡大しています。高品質の生物製剤が重視されることで、血漿処理技術の革新が進んでいます。
• 自動血漿採取の採用増加：自動血漿採取技術の採用が増加しており、産業に革命をもたらしています。自動化は血漿採取プロセスの効率と安全性を向上させ、より高い収率とドナー体験の向上をもたらします。施設がこのような先進的システムを導入することで、血漿製品の需要増に対応できるようになります。この動向は業務を合理化するだけでなく、収集プロセス中の不快感を最小限に抑えることで、より多くのドナーを惹きつけることにも役立っています。

目次

第1章 世界の血漿市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の血漿市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界血液プラスマ市場：成分別

• 概要
• 免疫グロブリン
• アルブミン
• 凝固因子濃縮物
• その他

第6章 世界の血漿市場：エンドユーザー別

• 概要
• 病院
• クリニック
• ラボ

第7章 血漿の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東

第8章 世界の血漿市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• CSL Behring
• Grifols
• Baxter International, Inc.
• Octapharma
• Shire（現Takeda Pharmaceutical Company傘下）
• Kedrion Biopharma
• China Biologic Products Holdings, Inc
• LFB Group, BIoTest AG.

第10章 付録

• 関連調査

Blood Plasma Market Size And Forecast

Blood Plasma Market size was valued at USD 41.26 Billion in 2024 and is projected to reach USD 83.44 Billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032.

• Blood plasma is the yellowish, liquid component of blood that remains after the blood cells (red cells, white cells, and platelets) have been removed. Comprising about 55% of total blood volume, plasma is primarily composed of water (around 90%), along with proteins, electrolytes, hormones, nutrients, and waste products.
• It serves as a crucial medium for transporting these substances throughout the body, playing an essential role in maintaining blood pressure, pH balance, and overall homeostasis.
• Plasma has numerous medical applications, particularly in transfusion medicine and therapeutic treatments. It is vital for the production of clotting factor concentrates for patients with hemophilia and is also used in the formulation of immunoglobulins to treat various immune deficiencies.
• Additionally, plasma-derived products, such as albumin and clotting factors, are critical in managing conditions like liver disease, shock, and burns. In recent years, plasma has also gained attention for its potential in regenerative medicine, including applications in wound healing and aesthetic treatments.

Global Blood Plasma Market Dynamics

The key market dynamics that are shaping the global blood plasma market include:

Key Market Drivers

• Rising Demand for Plasma-Derived Therapies: The rising demand for plasma-derived therapies is significantly driving the blood plasma market. Conditions such as hemophilia and immune deficiencies require these therapies for effective treatment. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Growing Awareness of Blood Donation: Growing awareness of the importance of blood donation is increasing the availability of plasma. Public health campaigns are encouraging more individuals to donate, thereby expanding the plasma supply. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases, such as autoimmune disorders, is boosting the need for plasma products. This trend emphasizes the essential role of plasma in managing complex health conditions. According to the Centers for Disease Control and Prevention (CDC), as of 2023, an estimated 6% of the U.S. population was living with an autoimmune disease, up from 4.5% in 2018.
• Rising Investment in Biotechnology: Rising investment in biotechnology and research is enhancing the development of plasma-derived products. Innovations in processing and formulation are leading to more effective therapies and expanded applications. The National Institutes of Health (NIH) reported that funding for research related to plasma-derived therapies reached USD 1.2 Billion in fiscal year 2023, a 15% increase from the previous year.
• Growing Regulatory Support for Plasma Products: Growing regulatory support for the safety and efficacy of plasma products is fostering market confidence. This supportive environment encourages manufacturers to invest in quality improvements and new product development. The FDA reported a 30% increase in the number of approved plasma-derived therapies in 2023 compared to 2020, reflecting a more streamlined approval process and growing confidence in these products.

Key Challenges:

• Increasing Regulatory Scrutiny: The increasing regulatory scrutiny surrounding blood plasma collection and use can hinder market expansion. Compliance with stringent guidelines adds complexity and costs for manufacturers and distributors.
• Rising Concerns over Donor Safety: Rising concerns about donor safety and the potential for adverse effects can affect plasma supply. These apprehensions may discourage individuals from donating, leading to shortages in plasma availability.
• Growing Public Perception Issues: Growing public perception issues related to blood donation and plasma products can create barriers to market growth. Misinformation or negative sentiments can deter potential donors and consumers alike.
• Growing Competition from Alternatives: Growing competition from alternative therapies and treatments poses a challenge to the blood plasma market. Emerging technologies may offer substitutes that reduce reliance on traditional plasma-derived therapies.

Key Trends

• Rising Focus on Immunoglobulin Therapies: The rising focus on immunoglobulin therapies is transforming the blood plasma market. As awareness grows about the effectiveness of these treatments for immune deficiencies and autoimmune diseases, demand is surging. Healthcare providers are increasingly prescribing immunoglobulin therapies, leading to greater investment in plasma collection and processing. This trend highlights the critical role of plasma-derived products in modern medicine.
• Growing Demand for Plasma-Derived Biologics: There is a growing demand for plasma-derived biologics, including clotting factors and albumin, essential for managing various medical conditions. This trend is fueled by an increasing prevalence of chronic diseases, surgical procedures, and trauma care needs. As more patients require these life-saving therapies, manufacturers are expanding their product lines to meet this demand. The emphasis on high-quality biologics is driving innovation in plasma processing technologies.
• Increasing Adoption of Automated Plasma Collection: The increasing adoption of automated plasma collection technologies is revolutionizing the industry. Automation improves the efficiency and safety of the collection process, resulting in higher yields and enhanced donor experience. As facilities implement these advanced systems, they can better meet the rising demand for plasma products. This trend not only streamlines operations but also helps attract more donors by minimizing discomfort during the collection process.

Global Blood Plasma Market Regional Analysis

Here is a more detailed regional analysis of the global blood plasma market:

North America

• North America leads the global blood plasma market, driven by advanced healthcare infrastructure, high awareness of plasma-derived therapies, and a well-established plasma collection network. The United States dominates the region's market share, with its robust regulatory framework and high plasma donation rates.
• According to the U.S. Food and Drug Administration, there were 943 licensed plasma collection centers in the country as of 2023, demonstrating the significant capacity for plasma collection and processing in the region.
• The region's dominance is further strengthened by the presence of major plasma fractionation companies and their ongoing investments in expanding production capabilities. Key players like CSL Limited and Grifols S.A. have been actively increasing their plasma collection and fractionation capacities to meet growing demand. In a recent development, Grifols announced in March 2024 the opening of a new plasma fractionation facility in North Carolina, USA, with an annual capacity of processing 6 million liters of plasma, potentially boosting the region's market position.

Asia Pacific

• The Asia Pacific region is experiencing rapid growth in the Blood Plasma Market, driven by improving healthcare infrastructure, increasing awareness of plasma-derived therapies, and rising prevalence of chronic diseases. Countries like China, India, and Japan are at the forefront of this expansion, with their governments investing heavily in healthcare systems and promoting plasma donation.
• According to China's National Medical Products Administration, the country's plasma-derived medicinal products market reached 30.8 billion yuan in 2023, highlighting the significant growth potential in the region.
• The market's growth is further propelled by the rising demand for immunoglobulins and other plasma-derived products for treating various immune deficiencies and rare diseases. Key players in the global blood plasma market are recognizing this potential and expanding their presence in Asia Pacific. In a recent development, Takeda Pharmaceutical Company Limited announced in February 2024 the completion of its new plasma fractionation facility in Guangzhou, China, with an annual production capacity of 1.2 million liters of plasma, aimed at meeting the growing demand for plasma-derived therapies in the region.

Global Blood Plasma Market: Segmentation Analysis

The Global Blood Plasma Market is segmented based on Component, End-User, And Geography.

Blood Plasma Market, By Component

• Immunoglobulin
• Albumin
• Coagulation Factor Concentrates
• Others

Based on Component, the Global Blood Plasma Market is bifurcated into Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Others. In the blood plasma market, immunoglobulin is the dominant component, primarily due to its critical role in treating various immune deficiencies and autoimmune disorders. Conversely, the albumin segment is rapidly growing, driven by its increasing applications in critical care settings, including surgeries and liver diseases, as well as its use in drug formulation. The rising demand for albumin-based therapies and its versatility in various medical applications are key factors contributing to this segment's expansion.

Blood Plasma Market, By End-User

• Hospitals
• Clinics
• Research Laboratories

Based on End-User, the Global Blood Plasma Market is bifurcated into Hospitals, Clinics, and Research Laboratories. In the blood plasma market, hospitals currently dominate as the primary end-user, driven by the high demand for plasma-derived therapies and transfusions in critical care settings. Meanwhile, the research laboratories segment is experiencing rapid growth, fueled by increasing investments in research related to plasma-derived products and their applications in various medical fields. The expansion of biopharmaceutical research and the development of new therapies utilizing plasma components are key factors contributing to the growth of this segment.

Blood Plasma Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Blood Plasma Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the blood plasma market, North America is the dominant region, primarily due to its advanced healthcare infrastructure, high prevalence of plasma-derived therapies, and significant investment in research and development. Conversely, the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditures, rising awareness of plasma therapies, and the expansion of healthcare facilities in countries like China and India. This growth is further supported by a rising incidence of chronic diseases and the demand for innovative treatment options, positioning Asia Pacific as a key area for future market expansion.

Key Players

The "Global Blood Plasma Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, Grifols, Baxter International, Inc., Octapharma, Shire (now part of Takeda Pharmaceutical Company), Kedrion Biopharma, Bio Products Laboratory, China Biologic Products Holdings, Inc., LFB Group, Biotest AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Plasma Market Key Developments

• In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments.
• In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD PLASMA MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD PLASMA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD PLASMA MARKET, BY Component

• 5.1 Overview
• 5.2 Immunoglobulin
• 5.3 Albumin
• 5.4 Coagulation Factor Concentrates
• 5.5 Others

6 GLOBAL BLOOD PLASMA MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Research Laboratories

7 GLOBAL BLOOD PLASMA MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL BLOOD PLASMA MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL Behring
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Grifols
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Baxter International, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Octapharma
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Shire (now part of Takeda Pharmaceutical Company)
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Kedrion Biopharma
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 China Biologic Products Holdings, Inc
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.9 LFB Group, Biotest AG.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 11.1 Related Research